Earnings call transcript: Redcentric tops EPS forecast in H2 2026, revenue misses

Redcentric reported H2 FY2026 EPS of $0.015, 36.4% above the $0.011 forecast, while revenue fell 2.3% year over year to $65.2 million and missed estimates by 4.5%. The sale of its data-center business generated £124.9 million net of costs, enabling £90 million of shareholder returns and reducing net debt to £2.8 million; shares rose 0.83% pre-market. Management targets adjusted EBITDA margin expansion to 20% from 13%-14% over two years, plans to reinstate dividends in FY2027, but expects VMware-related revenue conversion only in FY2028 and still faces contract runoff and public-sector procurement delays.

Analysis

RCN is transitioning from an asset-heavy, acquisition-led model to a lower-leverage managed-services platform, but the valuation rerating case rests on proving organic ARR growth—not on the mechanical earnings benefit from cost removal. The sale proceeds have reduced financial risk and create commercial credibility in regulated/public-sector tenders, where supplier solvency matters; this can improve win rates before it visibly changes reported revenue. Conversely, a 20% adjusted EBITDA margin target implies substantial operating leverage, so any failure to stabilize the revenue base would turn the restructuring into a shrinking-margin story and keep the equity trapped at a distressed small-cap multiple.

The VMware channel is strategically meaningful but economically back-end loaded. AVGO's tighter partner model transfers customer-support economics to a small number of resellers, potentially lifting RCN's recurring revenue and switching costs after conversion; however, customers choosing NTNX or hyperscalers are a real substitution risk, not merely delayed demand. NTNX is the cleaner liquid beneficiary if Broadcom licensing disruption drives migration; RCN only wins if delayed VMware decisions ultimately convert into contracted managed-service ARR rather than low-margin license pass-through.

Near term, the EPS beat should not command a material rerating because revenue miss and limited liquidity make the shares vulnerable to profit-taking after the capital return. Over 1-3 months, evidence of ARR stabilization, framework pipeline conversion, and incremental tender wins is the catalyst path. Over 6-18 months, the key debate is whether automation, offshore delivery and post-transition-services cost removal can produce margin expansion without impairing service levels in a regulated customer base.

Contrarian view: the market may be underestimating balance-sheet-driven tender eligibility and the value of a focused sovereign-services franchise, but may also be over-crediting management's margin target before disclosed bridge assumptions. The thesis is falsified if ARR remains negative after legacy runoff normalizes, adjusted EBITDA margin fails to expand by FY2027, or VMware pipeline converts predominantly to alternative platforms rather than RCN-managed deployments.

Key Decisions for Investors

• Maintain RCN as a watch-list long rather than initiate on the earnings reaction; require the next interim update to show non-negative underlying ARR and a quantified FY2027 cost-savings bridge. A position is attractive only if liquidity supports entry and valuation still discounts a sub-15% EBITDA-margin outcome; exit on renewed ARR deterioration or margin guidance below the path to 20%.
• For liquid exposure to VMware displacement over the next 6-12 months, prefer long NTNX versus AVGO. NTNX captures migration spend when customers reject revised VMware economics, while AVGO retains licensing power but faces customer-volume and partner-execution uncertainty; reassess if enterprise virtualization renewal data show VMware retention materially above expectations.
• Do not underwrite RCN's VMware opportunity into FY2027 estimates. Set an alert for disclosed contracted ARR, attach rates for managed services versus license resale, and conversion timing around the March 2027 VMware deadline; absent those data, the opportunity is an option value rather than an earnings catalyst.
• Monitor U.K. public-sector procurement awards and NHS budget/timing signals over the next 3-6 months. Framework inclusion alone is not revenue; a delayed Network Services 4 process or continued health-system purchasing friction would push any top-line recovery beyond the period when cost savings are expected to support earnings.